VISUfarma Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 160

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 3

  • Investments
  • 2

VISUfarma General Information

Description

Operator of an ophthalmic specialty pharmaceutical company intended to bring global innovation to European eye health. The company develops, markets, and distributes a wide portfolio of ophthalmology products and devices, enabling physicians, hospitals, and medical centers to provide patients with high-quality eye care.

Contact Information

Website
www.visufarma.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly PE-Backed
Corporate Office
  • Joop Geesinkweg 601
  • 1114 AB Amsterdam
  • Netherlands
Primary Industry
Pharmaceuticals
Other Industries
Other Consumer Non-Durables
Parent Company
Lupin
Vertical(s)
Life Sciences
Corporate Office
  • Joop Geesinkweg 601
  • 1114 AB Amsterdam
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

VISUfarma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore VISUfarma‘s full profile, request access.

Request a free trial

VISUfarma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of an ophthalmic specialty pharmaceutical company intended to bring global innovation to European eye health. T
Pharmaceuticals
Amsterdam, Netherlands
160 As of 2026

Copenhagen, Denmark
 

Winnipeg, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

VISUfarma Competitors (3)

One of VISUfarma’s 3 competitors is Xellia Pharmaceuticals, a Private Equity-Backed company based in Copenhagen, Denmark.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Xellia Pharmaceuticals Private Equity-Backed Copenhagen, Denmark
Kane Biotech Corporation Winnipeg, Canada
EyeD Pharma Venture Capital-Backed Seraing, Belgium
You’re viewing 3 of 3 competitors. Get the full list »

VISUfarma Patents

  • 23

    Total Documents Applications and Grants

  • Total Patents Families

  • 15

    Granted

  • Pending

  • Expiring in next 12 mo

VISUfarma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4093372-A1 Ophthalmic composition for the treatment of dry eye disease Active 23-Jan-2020
EP-4093372-B1 Ophthalmic composition for the treatment of dry eye disease Active 23-Jan-2020
ES-2982698-T3 Ophthalmic composition for the treatment of dry eye disease Active 23-Jan-2020
WO-2021148845-A1 Ophthalmic composition for the treatment of dry eye disease Inactive 23-Jan-2020
ES-2902831-T3 Cationic compounds and their use as antifungal and antimicrobial agents Active 25-Aug-2015 A61K31/787
To view VISUfarma’s complete patent history, request access »

VISUfarma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

VISUfarma Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore VISUfarma‘s full profile, request access.

Request a free trial

VISUfarma Investments (2)

VISUfarma’s most recent deal was a Later Stage VC with Tenpoint Therapeutics for . The deal was made on 20-Aug-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tenpoint Therapeutics 20-Aug-2026 Later Stage VC Drug Discovery
Nicox (European & International Commercial Operations) 05-Jul-2016 Buyout/LBO Pharmaceuticals
To view VISUfarma’s complete investments history, request access »

VISUfarma FAQs

  • When was VISUfarma founded?

    VISUfarma was founded in 2016.

  • Where is VISUfarma headquartered?

    VISUfarma is headquartered in Amsterdam, Netherlands.

  • What is the size of VISUfarma?

    VISUfarma has 160 total employees.

  • What industry is VISUfarma in?

    VISUfarma’s primary industry is Pharmaceuticals.

  • Is VISUfarma a private or public company?

    VISUfarma is a Private company.

  • What is the current valuation of VISUfarma?

    The current valuation of VISUfarma is .

  • What is VISUfarma’s current revenue?

    The current revenue for VISUfarma is .

  • Who are VISUfarma’s investors?

    GHO Capital and Nicox have invested in VISUfarma.

  • Who are VISUfarma’s competitors?

    Xellia Pharmaceuticals, Kane Biotech, and EyeD Pharma are competitors of VISUfarma.

  • When was VISUfarma acquired?

    VISUfarma was acquired on 01-Apr-2026.

  • Who acquired VISUfarma?

    VISUfarma was acquired by Lupin.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process